Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

Joseph E. Tota, Frank Struyf, Marko Merikukka, Paula Gonzalez, Aimée R. Kreimer, Dan Bi, Xavier Castellsagué, Newton S. De Carvalho, Suzanne M. Garland, Diane M. Harper, Naveen Karkada, Klaus Peters, Willy A J Pope, Carolina Porras, Wim Quint, Ana Cecilia Rodriguez, Mark Schiffman, John Schussler, Susan Skinner, Júlio Cesar TeixeiraAllan Hildesheim, Matti Lehtinen

    Research output: Contribution to journalArticlepeer-review

    29 Citations (Scopus)


    Background: Current HPV vaccines do not protect against all oncogenic HPV types. Following vaccination, type replacement may occur, especially if different HPV types competitively interact during natural infection. Because of their common route of transmission, it is difficult to assess type interactions in observational studies. Our aim was to evaluate type replacement in the setting of HPV vaccine randomized controlled trials (RCTs). Methods: Data were pooled from the Costa Rica Vaccine Trial (CVT; NCT00128661) and PATRICIA trial (NCT001226810) - two large-scale, double-blind RCTs of the HPV-16/18 AS04-adjuvanted vaccine - to compare cumulative incidence of nonprotected HPV infections across trial arms after four years. Negative rate difference estimates (rate in control minus vaccine arm) were interpreted as evidence of replacement if the associated 95% confidence interval excluded zero. All statistical tests were two-sided. Results: After applying relevant exclusion criteria, 21 596 women were included in our analysis (HPV arm = 10 750; control arm = 10 846). Incidence rates (per 1000 infection-years) were lower in the HPV arm than in the control arm for grouped nonprotected oncogenic types (rate difference = 1.6, 95% confidence interval [CI] = 0.9 to 2.3) and oncogenic/nononcogenic types (rate difference = 0.2, 95% CI = â '0.3 to 0.7). Focusing on individual HPV types separately, no deleterious effect was observed. In contrast, a statistically significant protective effect (positive rate difference and 95% CI excluded zero) was observed against oncogenic HPV types 35, 52, 58, and 68/73, as well as nononcogenic types 6 and 70. Conclusion: HPV type replacement does not occur among vaccinated individuals within four years and is unlikely to occur in vaccinated populations.

    Original languageEnglish
    Article numberdjw300
    JournalJournal of the National Cancer Institute
    Issue number7
    Publication statusPublished - 1 Jul 2017


    Dive into the research topics of 'Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials'. Together they form a unique fingerprint.

    Cite this